|
|
|
|
 Stafford O'Kelly,
President Molecular Diagnostics Abbott Molecular Appearing: DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 9.10am Learning from past success: overcoming the scientific, strategic and logistical challenges in the development of companion diagnostics
- Applying efficacy considerations to early co-development of cancer diagnostics and targeted therapy
- Comprehending the scientific, strategic and logistical challenges met in the co-development of drugs and diagnostics and how they are overcome
- Implications for the future outlook on the co-development of diagnostics and targeted cancer therapy
Stafford O'Kelly, President Molecular Diagnostics,
Abbott Molecular 10.30am Panel discussion: strategies for development, approval and reimbursement of cancer diagnostics in conjunction with targeted therapies
- The challenge: both the diagnostic and the drug must be approved and reimbursed.
- Considering the options for pharma companies in diagnostic development – internal development, external partnerships or outsourcing?#
- Strategies for overcoming regulatory and reimbursement concerns – who needs to make the initial investment? What are the regulatory considerations? Who ultimately pays for a diagnostic test?
Vice President Pharma Business Development,
QIAGEN Stafford O'Kelly, President Molecular Diagnostics,
Abbott Molecular Senior Director and Global Head of Diagnostics,
Pfizer Global R&D Vice President Scientific and Medical Affairs,
Veridex (a Johnson & Johnson compnay) |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
